Share Price and Basic Stock Data
Last Updated: November 22, 2025, 3:13 pm
| PEG Ratio | 38.41 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hindustan Bio Sciences Ltd operates in the Trading & Distributors industry, with its stock currently priced at ₹6.57 and a market capitalization of ₹6.74 Cr. The company has experienced fluctuating sales over the past several quarters, with the most recent quarterly sales reported at ₹0.32 Cr for September 2023. This represents a slight recovery from the previous quarter, where sales stood at ₹0.00 Cr in June 2023. However, the annual sales trend reveals a decline from ₹3.56 Cr in March 2019 to ₹0.92 Cr in March 2023, indicating a significant contraction in revenue generation capabilities. The trailing twelve months (TTM) revenue is reported at ₹0.70 Cr, which points to ongoing challenges in sustaining sales momentum. The volatility in sales figures suggests that the company may be facing difficulties in maintaining a steady customer base or operational efficiency, which is crucial for long-term growth.
Profitability and Efficiency Metrics
Profitability metrics for Hindustan Bio Sciences Ltd showcase a mixed performance. The company reported a net profit of ₹0.02 Cr, resulting in a remarkably high price-to-earnings (P/E) ratio of 337, indicating that the stock is trading at a premium compared to its earnings. The operating profit margin (OPM) stood at 0.00%, reflecting challenges in managing operational costs effectively. Efficiency metrics, such as return on equity (ROE) and return on capital employed (ROCE), were reported at 11.8% and 2.95%, respectively. The cash conversion cycle (CCC) is concerning at 198.27 days, suggesting that the company takes a long time to convert its investments in inventory and other inputs into cash flows. The high interest coverage ratio (ICR) at 71.29x indicates that the company is well-positioned to meet its interest obligations, but the lack of operational profitability raises questions about its long-term sustainability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hindustan Bio Sciences Ltd presents a unique picture, marked by the absence of borrowings and reserves, which stands at ₹0 Cr. This is notable, as it indicates that the company is not leveraging debt for growth, which can be a double-edged sword. On one hand, the lack of debt reduces financial risk; on the other, it may limit growth opportunities. The company reported a book value per share of ₹0.88, which is relatively low, and a price-to-book value (P/BV) ratio of 7.91x, suggesting that the stock is overvalued compared to its net asset value. The current ratio of 73.31x and quick ratio of 73.31x highlight exceptional liquidity; however, such high values may indicate underutilization of assets. Overall, while the absence of debt presents a stable financial position, it also reflects a lack of aggressive growth strategy.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Hindustan Bio Sciences Ltd shows that promoters hold 12.19% of the company, while the public holds a significant 87.81%. The number of shareholders increased to 11,405 as of March 2025, which indicates growing interest in the stock despite its operational challenges. The public’s dominant stake may reflect confidence in the company’s potential or a lack of alternatives in the market. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) raises concerns about broader market confidence in the company’s future prospects. The stable promoter holding suggests a commitment to the company, yet the high public ownership could also lead to volatility in stock price if sentiment shifts. Overall, the mix of ownership indicates a reliance on retail investors, which can be both a strength and a risk for the company.
Outlook, Risks, and Final Insight
The outlook for Hindustan Bio Sciences Ltd remains uncertain, primarily due to its inconsistent revenue trends and operational inefficiencies. While the company has demonstrated some ability to generate profit in certain quarters, the high P/E ratio combined with low OPM raises concerns about valuation sustainability. Risks include the potential for continued revenue declines, as evidenced by the historical trajectory, and the challenges posed by a lengthy cash conversion cycle. However, the absence of debt provides a cushion against financial distress, allowing the company some flexibility to navigate operational challenges. If Hindustan Bio Sciences Ltd can stabilize its sales and improve operational efficiency, it may create opportunities for growth. Conversely, failure to address these issues could lead to diminished investor confidence and a decline in market valuation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hindustan Bio Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mitshi India Ltd | 13.1 Cr. | 14.8 | 18.6/13.0 | 3.09 | 0.00 % | 0.36 % | 0.37 % | 10.0 | |
| MKP Mobility Ltd | 48.5 Cr. | 142 | 264/103 | 34.1 | 22.3 | 0.00 % | 19.6 % | 4.35 % | 10.0 |
| Mrugesh Trading Ltd | 0.84 Cr. | 3.45 | 3.45/0.48 | 277 | 0.00 % | 4.43 % | 3.81 % | 1.00 | |
| Mukta Agriculture Ltd | 6.42 Cr. | 2.96 | 7.84/2.52 | 10.2 | 0.00 % | 0.57 % | 0.63 % | 10.0 | |
| Hindustan Bio Sciences Ltd | 6.82 Cr. | 6.66 | 11.7/6.27 | 341 | 0.84 | 0.00 % | 2.95 % | 11.8 % | 2.00 |
| Industry Average | 282.00 Cr | 89.55 | 429.53 | 59.28 | 0.00% | 5.56% | 4.39% | 7.57 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.27 | 0.00 | 0.32 | 0.33 | 0.00 | 0.32 | 0.32 | 0.39 | 0.41 | 0.00 | 0.00 | 0.38 | 0.32 |
| Expenses | 0.29 | 0.07 | 0.27 | 0.31 | 0.12 | 0.26 | 0.26 | 0.35 | 0.34 | 0.05 | 0.04 | 0.28 | 0.32 |
| Operating Profit | -0.02 | -0.07 | 0.05 | 0.02 | -0.12 | 0.06 | 0.06 | 0.04 | 0.07 | -0.05 | -0.04 | 0.10 | 0.00 |
| OPM % | -7.41% | 15.62% | 6.06% | 18.75% | 18.75% | 10.26% | 17.07% | 26.32% | 0.00% | ||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.02 | -0.07 | 0.05 | 0.02 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.03 | -0.07 | 0.05 | 0.01 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
| EPS in Rs | -0.03 | -0.07 | 0.05 | 0.01 | -0.12 | 0.07 | 0.07 | 0.04 | 0.08 | -0.05 | -0.04 | 0.11 | 0.01 |
Last Updated: August 19, 2025, 1:50 pm
Below is a detailed analysis of the quarterly data for Hindustan Bio Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.32 Cr.. The value appears to be declining and may need further review. It has decreased from 0.38 Cr. (Mar 2025) to 0.32 Cr., marking a decrease of 0.06 Cr..
- For Expenses, as of Jun 2025, the value is 0.32 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.28 Cr. (Mar 2025) to 0.32 Cr., marking an increase of 0.04 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears to be declining and may need further review. It has decreased from 26.32% (Mar 2025) to 0.00%, marking a decrease of 26.32%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.11 (Mar 2025) to 0.01, marking a decrease of 0.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:09 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.25 | 0.75 | 1.26 | 1.01 | 1.03 | 3.56 | 1.94 | 1.03 | 0.43 | 0.92 | 1.05 | 0.81 | 0.70 |
| Expenses | 2.96 | 1.97 | 1.38 | 1.48 | 3.38 | 3.43 | 1.80 | 1.97 | 0.94 | 0.95 | 0.99 | 0.71 | 0.70 |
| Operating Profit | -0.71 | -1.22 | -0.12 | -0.47 | -2.35 | 0.13 | 0.14 | -0.94 | -0.51 | -0.03 | 0.06 | 0.10 | 0.00 |
| OPM % | -31.56% | -162.67% | -9.52% | -46.53% | -228.16% | 3.65% | 7.22% | -91.26% | -118.60% | -3.26% | 5.71% | 12.35% | 0.00% |
| Other Income | -0.04 | -0.01 | -1.92 | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Interest | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.22 | 0.18 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | -1.00 | -1.44 | -2.08 | -0.49 | -2.27 | 0.11 | 0.12 | -0.96 | -0.51 | -0.04 | 0.05 | 0.10 | 0.03 |
| Tax % | 0.00% | 0.69% | 0.00% | 0.00% | 0.00% | 0.00% | 33.33% | -2.08% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -0.99 | -1.46 | -2.09 | -0.49 | -2.28 | 0.11 | 0.08 | -0.94 | -0.52 | -0.04 | 0.06 | 0.10 | 0.02 |
| EPS in Rs | -0.97 | -1.42 | -2.04 | -0.48 | -2.22 | 0.11 | 0.08 | -0.92 | -0.51 | -0.04 | 0.06 | 0.10 | 0.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -47.47% | -43.15% | 76.56% | -365.31% | 104.82% | -27.27% | -1275.00% | 44.68% | 92.31% | 250.00% | 66.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.32% | 119.71% | -441.86% | 470.13% | -132.10% | -1247.73% | 1319.68% | 47.63% | 157.69% | -183.33% |
Hindustan Bio Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 202.78 | 155.73 | 136.15 | 169.85 | 113.40 | 171.22 | 255.88 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Inventory Days | 36.08 | 25.08 | 0.00 | 0.00 | 51.23 | 13.89 | 95.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days Payable | 84.88 | 39.01 | 44.82 | 7.58 | 185.31 | |||||||
| Cash Conversion Cycle | 153.97 | 141.80 | 136.15 | 169.85 | 119.80 | 177.54 | 166.03 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 |
| Working Capital Days | 186.56 | 111.93 | -63.73 | -191.53 | -170.10 | 85.10 | 86.55 | -148.83 | -500.81 | -226.14 | 312.86 | 441.60 |
| ROCE % | -9.91% | -16.40% | -1.91% | -8.43% | -49.08% | 2.62% | 2.51% | -23.75% | -16.67% | -1.30% | 1.52% | 2.95% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 |
| Diluted EPS (Rs.) | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 |
| Cash EPS (Rs.) | 0.09 | 0.06 | -0.03 | -0.50 | -0.90 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.88 | 0.78 | 0.72 | 0.76 | 1.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.88 | 0.78 | 0.72 | 0.76 | 1.27 |
| Revenue From Operations / Share (Rs.) | 0.79 | 1.03 | 0.89 | 0.42 | 1.01 |
| PBDIT / Share (Rs.) | 0.09 | 0.06 | -0.02 | -0.49 | -0.91 |
| PBIT / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.49 | -0.92 |
| PBT / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.50 | -0.93 |
| Net Profit / Share (Rs.) | 0.09 | 0.05 | -0.03 | -0.50 | -0.91 |
| PBDIT Margin (%) | 12.27 | 6.06 | -3.05 | -117.53 | -91.13 |
| PBIT Margin (%) | 12.24 | 5.41 | -3.67 | -118.32 | -91.91 |
| PBT Margin (%) | 12.07 | 5.06 | -4.11 | -119.47 | -92.57 |
| Net Profit Margin (%) | 12.39 | 5.47 | -4.38 | -120.18 | -91.07 |
| Return on Networth / Equity (%) | 11.13 | 7.16 | -5.41 | -65.75 | -72.04 |
| Return on Capital Employeed (%) | 2.92 | 1.69 | -1.81 | -27.41 | -46.54 |
| Return On Assets (%) | 2.94 | 1.70 | -1.23 | -17.39 | -26.95 |
| Long Term Debt / Equity (X) | 2.77 | 3.18 | 1.50 | 1.36 | 0.56 |
| Total Debt / Equity (X) | 2.77 | 3.18 | 3.29 | 2.75 | 1.42 |
| Asset Turnover Ratio (%) | 0.23 | 0.31 | 0.29 | 0.13 | 0.22 |
| Current Ratio (X) | 73.31 | 69.04 | 0.60 | 0.48 | 0.72 |
| Quick Ratio (X) | 73.31 | 69.04 | 0.60 | 0.48 | 0.72 |
| Interest Coverage Ratio (X) | 71.29 | 17.33 | -6.88 | -101.64 | -136.86 |
| Interest Coverage Ratio (Post Tax) (X) | 73.00 | 16.63 | -8.87 | -102.94 | -135.78 |
| Enterprise Value (Cr.) | 9.65 | 9.95 | 7.81 | 6.48 | 4.92 |
| EV / Net Operating Revenue (X) | 11.86 | 9.45 | 8.47 | 15.06 | 4.77 |
| EV / EBITDA (X) | 96.69 | 155.82 | -277.11 | -12.81 | -5.23 |
| MarketCap / Net Operating Revenue (X) | 8.80 | 7.06 | 5.91 | 10.05 | 2.98 |
| Price / BV (X) | 7.91 | 9.24 | 7.31 | 5.50 | 2.36 |
| Price / Net Operating Revenue (X) | 8.80 | 7.06 | 5.91 | 10.05 | 2.98 |
| EarningsYield | 0.01 | 0.01 | -0.01 | -0.11 | -0.30 |
After reviewing the key financial ratios for Hindustan Bio Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.10, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.10, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has increased from 0.06 (Mar 24) to 0.09, marking an increase of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.88. It has increased from 0.78 (Mar 24) to 0.88, marking an increase of 0.10.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.88. It has increased from 0.78 (Mar 24) to 0.88, marking an increase of 0.10.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.79. It has decreased from 1.03 (Mar 24) to 0.79, marking a decrease of 0.24.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 2. It has increased from 0.06 (Mar 24) to 0.09, marking an increase of 0.03.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 2. It has increased from 0.05 (Mar 24) to 0.09, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 12.27. This value is within the healthy range. It has increased from 6.06 (Mar 24) to 12.27, marking an increase of 6.21.
- For PBIT Margin (%), as of Mar 25, the value is 12.24. This value is within the healthy range. It has increased from 5.41 (Mar 24) to 12.24, marking an increase of 6.83.
- For PBT Margin (%), as of Mar 25, the value is 12.07. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 12.07, marking an increase of 7.01.
- For Net Profit Margin (%), as of Mar 25, the value is 12.39. This value exceeds the healthy maximum of 10. It has increased from 5.47 (Mar 24) to 12.39, marking an increase of 6.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.13. This value is below the healthy minimum of 15. It has increased from 7.16 (Mar 24) to 11.13, marking an increase of 3.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.92. This value is below the healthy minimum of 10. It has increased from 1.69 (Mar 24) to 2.92, marking an increase of 1.23.
- For Return On Assets (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 5. It has increased from 1.70 (Mar 24) to 2.94, marking an increase of 1.24.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 2.77. This value exceeds the healthy maximum of 1. It has decreased from 3.18 (Mar 24) to 2.77, marking a decrease of 0.41.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.77. This value exceeds the healthy maximum of 1. It has decreased from 3.18 (Mar 24) to 2.77, marking a decrease of 0.41.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.23. It has decreased from 0.31 (Mar 24) to 0.23, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 73.31. This value exceeds the healthy maximum of 3. It has increased from 69.04 (Mar 24) to 73.31, marking an increase of 4.27.
- For Quick Ratio (X), as of Mar 25, the value is 73.31. This value exceeds the healthy maximum of 2. It has increased from 69.04 (Mar 24) to 73.31, marking an increase of 4.27.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 71.29. This value is within the healthy range. It has increased from 17.33 (Mar 24) to 71.29, marking an increase of 53.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 73.00. This value is within the healthy range. It has increased from 16.63 (Mar 24) to 73.00, marking an increase of 56.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9.65. It has decreased from 9.95 (Mar 24) to 9.65, marking a decrease of 0.30.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 11.86. This value exceeds the healthy maximum of 3. It has increased from 9.45 (Mar 24) to 11.86, marking an increase of 2.41.
- For EV / EBITDA (X), as of Mar 25, the value is 96.69. This value exceeds the healthy maximum of 15. It has decreased from 155.82 (Mar 24) to 96.69, marking a decrease of 59.13.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.80. This value exceeds the healthy maximum of 3. It has increased from 7.06 (Mar 24) to 8.80, marking an increase of 1.74.
- For Price / BV (X), as of Mar 25, the value is 7.91. This value exceeds the healthy maximum of 3. It has decreased from 9.24 (Mar 24) to 7.91, marking a decrease of 1.33.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.80. This value exceeds the healthy maximum of 3. It has increased from 7.06 (Mar 24) to 8.80, marking an increase of 1.74.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hindustan Bio Sciences Ltd:
- Net Profit Margin: 12.39%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.92% (Industry Average ROCE: 5.56%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.13% (Industry Average ROE: 4.39%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 73
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 73.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 341 (Industry average Stock P/E: 429.53)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.77
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.39%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | H.No.8-2-269/S, Plot No.31, Sagar Co-Operative Housing Society, Hyderabad Telangana 500034 | pharma.hindustanbio@gmail.com www.hindustanbiosciences.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. J V R Mohan Raju | Chairman & Managing Director |
| Mrs. J Uma | Director |
| Mr. Jaison George | Director |
| Mr. Reji Abraham | Independent Director |
| Mr. B Nagi Reddy | Independent Director |
| Mr. G Prateek Reddy | Independent Director |